

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Pharmacology

ESPS manuscript NO: 21476

Title: Quinolone-based first, second and third-line therapies for *Helicobacter pylori*

Reviewer's code: 03009633

Reviewer's country: Poland

Science editor: Xue-Mei Gong

Date sent for review: 2015-07-15 12:06

Date reviewed: 2015-09-09 02:01

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript entitled "Quinolone based first, second and third line therapies for helicobacter pylori" summarizes the use of quinolones in eradication regimens for *H. pylori* infection. The authors present the use of levofloxacin in first, second and third-line treatment of *H. pylori*. The authors also describe the use of newer quinolones, such as moxifloxacin, sitafloxacin, gatifloxacin and gemifloxacin as new potential molecules that could be useful in therapy. The work represents review papers. Title and abstract well present the aims and design of the study. The work is properly constructed. Some comments to the Authors: 1. In the section: The use of levofloxacin in *H. pylori* eradication regimens, first line treatments and also in Table 1., the authors sometimes use the shortcut LTT and elsewhere ITT. Please clarify. It would be good also to put description of the shortcut under the table. 2. In my opinion there are too many references in the manuscript, however they are well selected. 3. A mistyping is noticed in the section: The use of levofloxacin in *H. pylori* eradication regimens, second line treatments: "lattoferrin" should read "lactoferrin". Overall, the study presents current knowledge about use of quinolones for *H. pylori* infection, it very useful and important from clinical point of view.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Pharmacology

ESPS manuscript NO: 21476

Title: Quinolone-based first, second and third-line therapies for *Helicobacter pylori*

Reviewer's code: 00075338

Reviewer's country: Portugal

Science editor: Xue-Mei Gong

Date sent for review: 2015-07-15 12:06

Date reviewed: 2015-09-21 06:48

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Duplicate publication	publication
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	language polishing	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear authors: I reviewed, with great interest, your manuscript entitled "Quinolone based first, second and third line therapies for *Helicobacter pylori*". It is an interesting work but, in my opinion, it has some flaws: I understand why you placed second line treatments in first place but would prefer a manuscript with the following order: First line, second line, rescue regimens. This is a mini-review but you emphasize a study with lactoferrin (totally unnecessary in this manuscript) and have not a single word about the type of PPI. I would also explore the possibility of a 14-day regimen. The English language/grammar must be thoroughly reviewed. Some examples: "Author contribution" – correct please. "However, fluoroquinolones are showing an increasing resistance rates, which could affect their effectiveness in the next future". I think this phrase is not correct. Probably you wanted to say: "However, *H. pylori* is showing an increasing resistance rate to fluoroquinolones, which could affect the effectiveness of such antibiotics in the near future." "excessive number" – correct please. Once more, congratulations for your work. I hope my suggestions can be useful for you.